title: Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample.
abstract: BACKGROUND
  It is assumed that hepatic steatosis plays a role in the development and progression of the metabolic syndrome and its cardiovascular sequelae. Low serum IGF1 levels might mediate these associations.
  
  
  OBJECTIVE
  The aims of this study were i) to investigate the associations of hepatic steatosis with serum IGF1 and IGF binding protein-3 (IGFBP-3) levels using ultrasound and serum alanine aminotransaminase (ALT) data to define hepatic steatosis, and ii) to analyze the specific role of alcohol consumption in this context.
  
  
  METHODS
  We analyzed data from the population-based Study of Health in Pomerania.
  
  
  METHODS
  We used data from 3863 subjects (1971 women) aged 20-79 years who had no history of viral hepatitis, liver cirrhosis, or malignant diseases. Liver hyperechogenicity was diagnosed using ultrasound. Serum IGF1 and IGFBP-3 levels were determined by automated two-site chemiluminescence immunoassays.
  
  
  RESULTS
  Hyperechogenic liver pattern was associated with low serum IGF1 levels and low serum IGF1/IGFBP-3 ratios. The lowest serum IGF1 and IGF1/IGFBP-3 values and highest IGFBP-3 levels were present in subjects who had a hyperechogenic liver pattern and increased serum ALT levels. All of these associations were independent of alcohol consumption.
  
  
  CONCLUSIONS
  Our data show that hepatic steatosis is associated with low serum IGF1 levels. This association is independent of alcohol consumption.
authors.affiliation: Institute of Community Medicine Institute of Clinical Chemistry and Laboratory Medicine Institute of Physiology Department of Internal Medicine B, University of Greifswald, Greifswald D-17487, Germany. voelzke@uni-greifswald.de
authors.forename: Henry
authors.initials: H
authors.lastname: Völzke
authors.forename: Matthias
authors.initials: M
authors.lastname: Nauck
authors.forename: Rainer
authors.initials: R
authors.lastname: Rettig
authors.forename: Marcus
authors.initials: M
authors.lastname: Dörr
authors.forename: Claire
authors.initials: C
authors.lastname: Higham
authors.forename: Georg
authors.initials: G
authors.lastname: Brabant
authors.forename: Henri
authors.initials: H
authors.lastname: Wallaschofski
mesh_terms: D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000428:Alcohol Drinking / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D003430:Cross-Sectional Studies; D005234:Fatty Liver / Q000097:blood* / Q000000981:diagnostic imaging / Q000201:enzymology; D005260:Female; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3; D018969:Insulin-Like Growth Factor Binding Proteins / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D014168:Transferrin / Q000378:metabolism; D014463:Ultrasonography; D055815:Young Adult; D005723:gamma-Glutamyltransferase / Q000097:blood
chemical_list: C515497:IGFBP3 protein, human; D018972:Insulin-Like Growth Factor Binding Protein 3; D018969:Insulin-Like Growth Factor Binding Proteins; D014168:Transferrin; D007334:Insulin-Like Growth Factor I; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase